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Thanks to the improvement in respirator care the mortality of newborns with respiratory insufficiency has decreased markedly during the last decade.
Nevertheless, the number of newborn infants who die of pulmonary failure inspite'of maximal efforts is still large enough so that additional means of assisting respiratory gas ex^-change must be found.
Extracorporeal membrane oxygenation has been evaluated for this purpose (3).
Membrane oxygenators cause less hemolysis than bubble oxygenators and thus can be used for several days instead of only hours.
Such a temporary artificial lung should be an appropriate means of support for newborns whose respiratory failure is due to a reversible disease e.g. mecomum aspiration (MAS), persistent fetal circulation (RFC), and respiratory distress syndrome (RDS).
The extracorporeal circuit has a volume of 350 ml and is primed with blood.
For venoarterial (VA) and venovenous CW) ECMO blood is drained from the right atrium by gravity through a catheter in the the right internal jugular vein.
A roller pump pumps the blood through a Kolobow Sci-Med membrane oxygenator and a heat exchanger back into the patient via the right common carotid artery for VA ECMO and to a femoral vein for VV ECMO (1). A mixture of 95% 0 ? und 5% C0 2 provides the necessary gas gradients for the membrane lung.
The blood is heparinized and the activated clotting time is checked frequently.
Consumption thrombocytopeni s is corrected with platelet transfusions.
Medications and parenteral nutrition solutions are given via the ECMO circuit.
The patient remains intubated oh a ventilator with low pressure, rate, .and 0 2 settings.
A daily trial without ECMO informs about any improvement in lung function.
Patients are selected for ECMO if they have not responded to maximal ventilatory, medical, and surgical means. During the first day of life the Neonatal Pulmonary Insufficiency Index (ΝΡΙΙ) C*O -a scoring system based on pH and 0 2 requirements -of over 80% chance of dying is an indication.
Major malformations, birthweight under 1000 grams, and intraventr icu1ar hemorrhage ClVH) are contrai nd i cat i ons. Other problems include hemothorax, membrane failure, transient renal failure, and seizures.
The latter may, howver, have been caused by the preceding birth .asphyxia in infants with MAS.
The ligature of the right carotid artery has caused no ill effects as determined by clinical, ultrasound, and Doppler examinations. All infants are followed up as to their physical and neurological development. Preliminary evidence from the older survivors shows them to be similar to non-ECMO survivors of severe neonatal illness. ECMO requires major technical and personnel resources. A lengthy training period for a special team in an animal perfusion laboratory is necessary.
Therefore we are now evaluating its efficacy and cost effectiveness in a randomized controlled study before recommending a more general clinical introduction of ECMO. L i terature: 
